ArticleBMC women's health2025
Changing trends in the global burden of polycystic ovarian syndrome-related infertility over the past 30 years: retrospective data analysis of the global burden of disease study 2019.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From Gene Function to Precision Intervention: CRISPR/Cas9 and Stem Cell-Based Strategies as Emerging Disease-Modifying Approaches in PMOS.Stem cell reviews and reports · 2026Review
- Living with PCOS: A Narrative of its Biology, Diagnosis, and Evolving Treatment.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Burden and Risk Factor Patterns of Reproductive System Tumors and Non-Tumor Diseases Among Asian Women, 1990-2021: Evidence from the GBD Study.International journal of women's health · 2026Article
- Quercetin modulates the interplay between DNMT gene expression, oxidative stress, and trace elements in DHEA-induced polycystic ovary syndrome rat model.Scientific reports · 2025Article
- Global, regional, and national burden of infertility attributable to polycystic ovary syndrome, 1990-2021: results from the Global Burden of Disease Study 2021.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesPolycystic ovary syndrome (PCOS) represents a significant and persistent metabolic disorder, emerging as a leading factor contributing to infertility. Despite its profound impact, there remains an inadequate understanding of the global burden of PCOS-related infertility across diverse regions and countries. The aim of this study was to evaluate the global, regional, and national burden of PCOS-related infertility from 1990 to 2019.
methodsThe data utilized in this study were derived from the Global Burden of Disease Study 2019. The global burden of PCOS-related infertility was collected and subsequently categorized based on age and sociodemographic index (SDI) spanning the period from 1990 to 2019. Temporal trends in PCOS-related infertility over the past three decades were scrutinized employing joinpoint regression analysis, enabling the determination of annual percentage change (APC) and average annual percentage changes (AAPCs). The association between the age-standardized prevalence rate (ASPR), age-standardized YLD rate (ASYR), and the AAPCs in ASPR and ASYR and the SDI was performed using linear regression analysis. Additionally, the Slope Index of Inequality (SII) and the Relative Concentration Index were employed to assess the inequalities in the distribution of infertility burdens related to PCOS.
resultsGlobally, the number of prevalent cases and YLDs due to PCOS-related infertility increased from 5,997,589 (95% UI: 3,772,636-8,764,813), and 35,201 (95% UI: 13,282 - 80,010) in 1990 to 12,131,849 (95% UI: 7,625,027 - 17,945,905), and 69,694 (95% UI: 26,756 - 160,420) in 2019, respectively. The age-standardized rates of prevalence and YLDs consistently increased over the same period, with respective AAPCs of 2.45 (95% CI: 2.4-2.5) and 2.37 (95% CI: 2.32-2.43), respectively. The number of prevalent cases and rate of PCOS peaked in the 25-29 years. Populations with high SDI had the highest ASPRs and ASYRs of PCOS-related infertility, while populations with low SDI exhibited more pronounced upward trends. Additionally, linear regression analysis revealed that ASPRs and ASYRs were positively correlated with SDI (R = 0.419 and 0.433, respectively, all P < 0.0001), and the AAPCs in ASPRs and ASYRs were negatively correlated with SDI (R= - 0.570 and - 0.571, respectively, all P < 0.0001). The SII for prevalent cases and YLDs were 121.94 (95% CI: 94.66-149.23) and 0.75 (95% CI: 0.55-0.85) to 146.56 (95% CI: 110.27-182.86) and 0.91 (95% CI: 0.71-1.03), respectively.
conclusionThe prevalent cases and YLDs, along with the ASPRs and ASYRs attributable to PCOS-related infertility, exhibited a consistent upward trajectory over the past 30 years. This escalation was closely associated with factors such as age, socioeconomic status, and geographic location. It is crucial to bolster healthcare management, devise timely and efficacious prevention and control strategies, and provide epidemiological theoretical evidence to alleviate the burden of PCOS-related infertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.